How has been the historical performance of Clinitech Lab?
2025-11-13 00:42:17Answer: The historical performance of Clinitech Lab shows a mixed trend in financial metrics over the past three years. Breakdown: Clinitech Lab's net sales increased from 6.35 Cr in Mar'23 to 6.40 Cr in Mar'24, and further to 8.23 Cr in Mar'25, indicating a positive growth trajectory. Total operating income followed a similar pattern, reaching 8.23 Cr in Mar'25. However, total expenditure also rose significantly from 4.99 Cr in Mar'23 to 7.40 Cr in Mar'25, leading to a decline in operating profit (PBDIT) from 1.36 Cr in Mar'23 to 1.06 Cr in Mar'25. Profit before tax showed a decrease from 0.86 Cr in Mar'23 to 0.55 Cr in Mar'25, while profit after tax also fell from 0.61 Cr in Mar'23 to 0.39 Cr in Mar'25. Despite these declines, earnings per share (EPS) decreased from 4.07 in Mar'23 to 1.71 in Mar'25. On the balance sheet, total assets grew from 5.88 Cr in Mar'23 to 10.55 Cr in Mar'25, with total liabiliti...
Read full news articleBoard Meeting Outcome for Outcome Of 09Th Board Meeting Held Today At Its Registered Office
06-Feb-2026 | Source : BSEWe hereby inform that the Board of Directors of the company at its meeting held today i.e. February 06 2026 held at registered office without intimation have: Approved formation of Subsidiary in the name & style as Analog IVD Solutions Private Limited and subscribe the memorandum; Approved availment of Term loan of INR 22.50 Lakhs from Bank of Baroda.
Board Meeting Outcome for Outcome Of 08Th Board Meeting For FY 2025-26 Thorugh Video Conferencing
27-Jan-2026 | Source : BSEOutcome of 08th Board meeting for FY 2025-26 through video conferencing without intimation for the following agendas: Approved the formation of a subsidiary of the company; To consider and approve re-constitution of Internal Complaint Committee (ICC) and revision in POSH Policy thereto
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
09-Jan-2026 | Source : BSECertificate under Reg 74(5) of SEBI (DP) Regulations for the quarter ended December 31 2025
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available






